Position in ABSI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$696,657
New position
Shares Held
232,219
first reported quarter
Ownership
0.149%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Vestal Point Capital, LP holds $2,697,459,670 across 67 Biotechnology names. ABSI ranks #66 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,375,000 | $230,968,750 | |
| 2 | BMRN |
Biomarin Pharmaceutical Inc
|
3,575,000 | $201,951,750 | |
| 3 | ABVX |
Abivax S.A.
|
1,500,000 | $167,025,000 | |
| 4 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
2,275,000 | $142,642,500 | |
| 5 | ELVN |
Enliven Therapeutics, Inc.
|
3,250,000 | $127,400,000 | |
| 6 | BCAX |
Bicara Therapeutics Inc.
|
5,425,000 | $107,903,250 | |
| 7 | NRIX |
Nurix Therapeutics, Inc.
|
6,500,000 | $100,750,000 | |
| 8 | APGE |
Apogee Therapeutics, Inc.
|
1,100,000 | $92,587,000 |
All Filings in ABSI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $696,657 | 232,219 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||